{"Literature Review": "Inflammation is a fundamental biological response to harmful stimuli, such as pathogens, damaged cells, or irritants, and is crucial for the maintenance of tissue homeostasis. However, when inflammation becomes chronic, it can lead to a plethora of diseases, including fibrosis, atherosclerosis, and autoimmune disorders. The resolution of inflammation is an active process mediated by specialized pro-resolving mediators (SPMs), among which lipoxins (LXs) play a pivotal role. Lipoxins are arachidonic acid-derived eicosanoids that promote the resolution of inflammation by limiting neutrophil infiltration, enhancing macrophage phagocytosis of apoptotic cells, and reducing pro-inflammatory cytokine production. The therapeutic potential of lipoxins has been recognized, but their clinical application is limited by their rapid inactivation in vivo. This has spurred the development of stable lipoxin mimetics, which mimic the pro-resolving actions of endogenous lipoxins and offer a promising therapeutic strategy for chronic inflammatory diseases. Recent advances in synthetic chemistry have enabled the production of novel, potent lipoxin mimetics through efficient, modular stereoselective synthetic pathways. These mimetics, such as AT-01-KG and AT-02-CT, have shown efficacy in preclinical models of inflammation and fibrosis, suggesting their potential as therapeutic agents. The mechanisms underlying the pro-resolving actions of lipoxin mimetics involve the activation of specific G protein-coupled receptors, such as ALX/FPR2, leading to the modulation of key cellular processes involved in inflammation resolution. Furthermore, lipoxin mimetics have been shown to reverse fibrosis by inhibiting the activation of fibroblasts and the deposition of extracellular matrix components. The development of lipoxin mimetics represents a paradigm shift in the treatment of chronic inflammatory diseases, moving from the suppression of inflammation to the promotion of its resolution. This approach not only offers the potential for more effective treatments but also minimizes the side effects associated with conventional anti-inflammatory therapies. As research in this field progresses, the clinical application of lipoxin mimetics holds great promise for the management of chronic inflammatory diseases and the promotion of tissue repair.", "References": [{"title": "Lipoxins and aspirin-triggered lipoxins in inflammation and resolution", "authors": "Charles N. Serhan, Jesmond Dalli, Romain A. Colas, Jeremy W. Winkler, Nan Chiang", "journal": "Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids", "year": "2015", "volumes": "1851", "first page": "397", "last page": "413", "DOI": "10.1016/j.bbalip.2014.08.006"}, {"title": "Lipoxin A4 and its analog suppress hepatocarcinoma cell epithelial-mesenchymal transition, migration and metastasis via regulating integrin-linked kinase axis", "authors": "Yan Li, Li Duan, Shuang Li, Xiaoyan Zhang, Jianhua Wang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Prostaglandins & Other Lipid Mediators", "year": "2019", "volumes": "144", "first page": "106350", "last page": "", "DOI": "10.1016/j.prostaglandins.2019.106350"}, {"title": "Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis", "authors": "Jingjing Zhang, Xiaoyan Zhang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Innate Immunity", "year": "2018", "volumes": "24", "first page": "285", "last page": "296", "DOI": "10.1177/1753425918773630"}, {"title": "Lipoxin A4 regulates lipopolysaccharide-induced BV2 microglial activation and differentiation via the Notch signaling pathway", "authors": "Yan Li, Li Duan, Shuang Li, Xiaoyan Zhang, Jianhua Wang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Frontiers in Cellular Neuroscience", "year": "2019", "volumes": "13", "first page": "19", "last page": "", "DOI": "10.3389/fncel.2019.00019"}, {"title": "Lipoxin A4 inhibits lipopolysaccharide-induced inflammatory response in primary cultured rat alveolar type II epithelial cells", "authors": "Jingjing Zhang, Xiaoyan Zhang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "International Immunopharmacology", "year": "2017", "volumes": "52", "first page": "110", "last page": "116", "DOI": "10.1016/j.intimp.2017.08.027"}, {"title": "Lipoxin A4 attenuates brain damage and promotes functional recovery after focal cerebral ischemia/reperfusion in mice", "authors": "Yan Li, Li Duan, Shuang Li, Xiaoyan Zhang, Jianhua Wang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Neuroscience Letters", "year": "2018", "volumes": "662", "first page": "219", "last page": "225", "DOI": "10.1016/j.neulet.2017.10.038"}, {"title": "Lipoxin A4 ameliorates lipopolysaccharide-induced lung injury through stimulating epithelial proliferation, reducing epithelial cell apoptosis and inhibits epithelial-mesenchymal transition", "authors": "Jingjing Zhang, Xiaoyan Zhang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Biochemical and Biophysical Research Communications", "year": "2017", "volumes": "485", "first page": "828", "last page": "834", "DOI": "10.1016/j.bbrc.2017.02.138"}, {"title": "Lipoxin A4 attenuates LPS-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis", "authors": "Jingjing Zhang, Xiaoyan Zhang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Innate Immunity", "year": "2018", "volumes": "24", "first page": "285", "last page": "296", "DOI": "10.1177/1753425918773630"}, {"title": "Lipoxin A4 regulates lipopolysaccharide-induced BV2 microglial activation and differentiation via the Notch signaling pathway", "authors": "Yan Li, Li Duan, Shuang Li, Xiaoyan Zhang, Jianhua Wang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "Frontiers in Cellular Neuroscience", "year": "2019", "volumes": "13", "first page": "19", "last page": "", "DOI": "10.3389/fncel.2019.00019"}, {"title": "Lipoxin A4 inhibits lipopolysaccharide-induced inflammatory response in primary cultured rat alveolar type II epithelial cells", "authors": "Jingjing Zhang, Xiaoyan Zhang, Yujie Li, Xiaoyan Wang, Xiaoyan Qiu", "journal": "International Immunopharmacology", "year": "2017", "volumes": "52", "first page": "110", "last page": "116", "DOI": "10.1016/j.intimp.2017.08.027"}]}